A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD) for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer).
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2010
At a glance
- Drugs Tasadenoturev (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- 25 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Actual patient number (26) added as reported by ClinicalTrials.gov.
- 25 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.